OncoMatch/Clinical Trials/NCT06344156
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Is NCT06344156 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy for pancreatic cancer.
Treatment: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy — The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage I, II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Received antitumor chemotherapy...within 2 weeks prior to first vaccination
Cannot have received: radiation therapy
Received...radiation therapy...within 2 weeks prior to first vaccination
Cannot have received: immunotherapy
Received...immunotherapy within 2 weeks prior to first vaccination
Cannot have received: neoadjuvant therapy
not receiving neoadjuvant therapy
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate bone marrow and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06344156 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior chemotherapy, radiation therapy, immunotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages